Trial Profile

Relative Bioavailability of 2 Ixekizumab Test Formulations Compared to the Commercial Formulation in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixekizumab (Primary)
Indications Ankylosing spondylitis; Bullous pemphigoid; Erythrodermic psoriasis; Pityriasis rubra pilaris; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Pyoderma gangrenosum; Rheumatoid arthritis; Spondylarthritis
Focus Pharmacokinetics
Sponsors Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

16 Jun 2019 Status changed from active, no longer recruiting to completed.
15 Mar 2019 Status changed from recruiting to active, no longer recruiting.
23 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com